Toronto Stock Exchange Symbol: MS
~ "Anatomy of a Deal - BioMS Medical and Eli Lilly and Company" ~
EDMONTON, May 1 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, BioMS Medical and Buu Le Lien, Senior Manager, Corporate Business Development, Eli Lilly and Company, will take part in a speciality panel session at BioFinance 2008 in Toronto entitled "Anatomy of a Deal - BioMS Medical and Eli Lilly and Company."
Also participating in the panel session will be Nitin Kaushal, Managing
Director, Desjardins Securities and Jeremy Webster, Executive Vice
President & Director, Deloitte & Touche. The moderator for the session will
be Cheryl Reicin, Partner, Torys LLP.
WHEN: Wednesday May 7th @ 3:00 PM (Eastern Time)
WHERE: Toronto Marriott, Toronto
Kevin Giese will also provide a corporate presentation at 11:00am (Eastern Time) on Wednesday May 7th.
About BioFinance 2008
BioFinance 2008 is the Canadian Life Science industry's leading investor conference. The meeting brings together key industry players to consider investment opportunities and issues affecting companies in biotechnology, medical devices, diagnostics and research tools. Participants include senior life science executives, institutional and venture capital investors, industry analysts, corporate finance executives and experts from the scientific and medical communities in Canada, the United States, Europe and Asia. For more information visit http://www.biofinance.ca/
About BioMS Medical Corp.
BioMS Medical is a biotechnology company engaged in the development and
commercialization of novel therapeutic technologies. BioMS Medical's lead
technology, MBP8298, i
|SOURCE BioMS Medical Corp.|
Copyright©2008 PR Newswire.
All rights reserved